A better understanding of the factors that contribute to heterogeneous outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically needed to improve patient management and outcomes. The Sarcomeric Human Cardiomyopathy Registry (SHaRe) was established to provide the scale of data required to address these issues, aggregating longitudinal datasets curated by eight international HCM specialty centers.

In this study researchers looked at whether the genetic changes in the heart myosin that cause HCM tend to occur more often in certain areas of the molecule. In addition, the researchers looked at how different genetic changes contribute to differences in disease onset and disease outcomes of patients with Hypertrophic Cardiomyopathy.